TMCnet

BostonGene RNA Transcriptome Profiling Reveals New ADC Targets in Advanced Solid Tumors

BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...
Business Wire

Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...
Phys.org

Simultaneously decoding the transcriptome, epigenome and 3D genome within a single cell

The origin of many diseases begins at the cellular level and involves multiple molecular interactions. However, previous methods have struggled to accurately observe changes in individual cells.

Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
ascopubs.org

Prediction of Patients With High-Risk Osteosarcoma on the Basis of XGBoost Algorithm Using Transcriptome and Methylation Data From SGH-OS Cohort

Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study Osteosarcoma (OS) is the most ...
Business Wire

Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ ...